"Company","Parent Company","Penalty Amount","Subtraction From Penalty","Penalty Amount Adjusted For Eliminating Multiple Counting","Penalty Year","Penalty Date","Offense Group","Primary Offense","Secondary Offense","Description","Level of Government","Action Type","Agency","Civil/Criminal","Prosecution Agreement","Court","Case ID","Private Litigation Case Title","Lawsuit Resolution","Facility State","City","Address","Zip","NAICS Code","NAICS Translation","HQ Country of Parent","HQ State of Parent","Ownership Structure","Parent Company Stock Ticker","Major Industry of Parent","Specific Industry of Parent","Info Source","Notes"
"Galena Biopharma, Inc.","SELLAS Life Sciences Group","$200,000","$0","$200,000","2017","20170410","financial offenses","accounting fraud or deficiencies","","","federal","agency action","Securities and Exchange Commission","civil","","","","","","","","","","","","USA","New York","publicly traded","SLS","pharmaceuticals","pharmaceuticals","https://www.sec.gov/litigation/admin/2017/33-10337.pdf",""
"Galena Biopharma Inc.","SELLAS Life Sciences Group","$7,550,000","$0","$7,550,000","2017","20170908","government-contracting-related offenses","False Claims Act and related","kickbacks and bribery","Galena Biopharma Inc. agreed to pay more than $7.55 million to resolve allegations that it paid kickbacks to doctors to induce them to prescribe its fentanyl-based drug Abstral. The allegations arose from a whistleblower suit filed under the False Claims Act.","federal","agency action","U.S. Attorney-District of New Jersey","civil","","","","","","","","","","","","USA","New York","publicly traded","SLS","pharmaceuticals","pharmaceuticals","https://www.justice.gov/usao-nj/pr/galena-biopharma-inc-pay-more-755-million-resolve-alleged-false-claims-related-opioid",""
